Cramer: A stock with lots of ways to win

CNBC
Cramer: A stock with lots of ways to win
.

View photo

SelectStock | Getty Images

"I like nothing more than to find companies that give you lots of ways to win," Cramer said. "That's this stock, to a tee."

The Mad Money host was talking about Johnson & Johnson (JNJ), a stock that he suggests buying if the overall market declines.

Long-term Cramer sees many catalysts that should drive Johnson & Johnson higher. They follow:

Growth

" JNJ has the best organic growth of any of the major drug companies, and its accelerating. That's what's so crucial. This market thrives on growth," Cramer said.

Cash

"It has the best balance sheet in the industry," Cramer insisted. And all that cash allows JNJ to move very strategically."

Promising Drugs

For example, JNJ has a piece of "a revolutionary anti-blood cancer drug, which which has shown an incredible 68% response rate on treatment resistant non-hodgkins lymphoma. This drug alone could do as much as $6.5 billion in sales in just a few years."

Brand Names

The consumer products division has some of the best known products on the market including the now rejuvenated Tylenol business," Cramer noted.

Strong CEO

Under Alex Gorsky, "Johnson & Johnson has gone from being poorly managed to being among the best managed companies in health care."

-----------------------------------------------------------
Read More from Mad Money with Jim Cramer
What's driving Google? Cramer explains
Why Cramer sees upside in Apple
Amid pullback, this stock a buy: Cramer
-----------------------------------------------------------

All told, Cramer sees every reason for shares to climb. It's could attract growth investors, defensive investors, those looking for a spin-off and others betting on promising new treatments.

"I know the stock's up 31% since the year began, but I think that's just the beginning. Due to the catalysts outlined above there are just too many ways to win. "I suspect a multi-year move lies ahead," Cramer said. "This may be the best buy and hold (and Cramer doesn't like that term) on the entire Big Board."


More From CNBC
View Comments